Achilles Therapeutics plc
ACHL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.48 | -0.41 | -0.3 | -0.47 |
| % Growth | -17.1% | -36.7% | 36.2% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |